BiotechTube
ImmunSYS

ImmunSYS

San Diego, United States· Est.
immunsys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

ImmunSYS is a private, preclinical-stage biotech developing biologics for autoimmune and inflammatory disorders. Operating from the San Diego biotech hub, the company is building a pipeline based on a proprietary platform targeting immune dysregulation. As a pre-revenue entity, its success hinges on advancing its lead candidates into clinical trials and securing strategic partnerships or further investment. The company operates in a high-potential but intensely competitive therapeutic area.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

Proprietary biologics platform targeting immune system dysregulation to restore homeostasis, likely involving monoclonal antibodies or fusion proteins against novel immunology targets.

Funding History

1
Total raised:$2M
Grant$2M

Opportunities

The large and growing global market for autoimmune therapies presents a multi-billion dollar opportunity.
Significant unmet need remains for patients who are refractory to existing treatments, creating space for novel, targeted biologics.
Success in a major indication could position the company as an attractive partner or acquisition target for large pharma.

Risk Factors

High risk of preclinical and clinical failure inherent to novel drug development.
Intense competition from large biopharma and numerous biotechs with advanced pipelines.
Dependence on securing additional funding to advance programs into costly clinical trials.

Competitive Landscape

The autoimmune/inflammatory space is one of the most competitive in biopharma, dominated by blockbuster drugs from companies like AbbVie, Johnson & Johnson, and Amgen. ImmunSYS will compete against these giants and a crowded field of biotechs developing next-generation mechanisms (e.g., JAK inhibitors, TYK2 inhibitors, cell therapies). Differentiation will require demonstrating superior efficacy or safety in areas of high unmet need.

More companies in Biologics / Biosimilars →More companies in United States →